Drug-induced liver injury: Past, present and future

Pharmacogenomics

Volumn 11, Issue 5, 2010, Pages 607-611

  Daly, Ann K ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Co amoxiclav; Drug induced liver injury; Flucloxacillin; Genome wide association; HLA; Isoniazid; N acetyltransferase 2; Polymorphism

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ARYLAMINE ACETYLTRANSFERASE; CARRIER PROTEIN; CYTOCHROME P450 2E1; DICLOFENAC; FLUCLOXACILLIN; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 2B7; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; HLA A ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; ISONIAZID; MANGANESE SUPEROXIDE DISMUTASE; PROTEIN ABCB11; PROTEIN ABCC2; TACRINE; TICLOPIDINE; TOLCAPONE; TROGLITAZONE; UNCLASSIFIED DRUG; XIMELAGATRAN;

ACETYLATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; IMMUNE RESPONSE; INCIDENCE; NOTE; OXIDATIVE STRESS; PHENOTYPE; TOXIC HEPATITIS;

ALLELES; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ARYLAMINE N-ACETYLTRANSFERASE; DRUG-INDUCED LIVER INJURY; FORECASTING; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; ISONIAZID; PHARMACEUTICAL PREPARATIONS; RISK FACTORS;

EID: 77951553451     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.24     Document Type: Note

References (34)

1. Kaplowitz N: Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4(6), 489-499 (2005).
2. Stricker BH, Blok A P, Claas FH, van Parys GE, Desmet VJ: Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology 8(3), 599-606 (1988).
3. Berson A, Freneaux E, Larrey D et al.: Possible role of HLA in hepatotoxicity-an exploratory-study in 71 patients with drug-induced idiosyncratic hepatitis. J. Hepatol. 20(3), 336-342 (1994).
4. Hautekeete ML, Horsmans Y, van Waeyenberge C et al.: HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 117(5), 1181-1186 (1999).
5. O'Donohue J, Oien KA, Donaldson P et al.: Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 47(5), 717-720 (2000).
6. Eichelbaum M, Musch E, Castroparra M, Vonsassen W: Isoniazid hepatotoxicity in relation to acetylator phenotype and isoniazid metabolism. Br. J. Clin. Pharmacol. 14(4), P575-P576 (1982).
7. Gronhagen-Riska C, Hellstrom PE, Froseth B: Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of Tuberculosis. Am. Rev. Respir. Dis. 118(3), 461-466 (1978).
8. Dickinson DS, Bailey WC, Hirschowitz BI, Soong SJ, Eidus L, Hodgkin MM: Risk factors for isoniazid (NIH)-induced liver dysfunction. J. Clin. Gastroenterol. 3(3), 271-279 (1981).
9. Mitchell JR, Thorgeirsson UP, Black M et al.: Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin. Pharmacol. Ther. 18(1), 70-79 (1975).
10. Ohno M, Yamaguchi I, Yamamoto I et al.: Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int. J. Tuberc. Lung Dis. 4(3), 256-261 (2000).
11. Daly AK, Donaldson PT, Bhatnagar P et al.: HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to fucloxacillin. Nat. Genet. 41, 816-819 (2009).
12. Andrade RJ, Lucena MI, Alonso A et al.: HLA class II genotype infuences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 39(6), 1603-1612 (2004).
13. Mallal S, Nolan D, Witt C et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 359, 727-732 (2002).
14. Donaldson PT, Bhatnagar P, Graham J et al.: Susceptibility to drug induced liver injury determined by HLA class II genotype. 59th Annual Meeting of the American Association for the Study of Liver Diseases. Hepatology 48(4), 396A-397A (2008) (Meeting Abstract 196)
15. Kindmark A, Jawaid A, Harbron CG et al.: Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 8, 186-195 (2008).
16. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK: Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during anti-Tuberculosis treatment. Am. J. Respir. Crit. Care Med. 166(7), 916-919 (2002).
17. Huang YS, Chern HD, Su WJ et al.: Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for anti-Tuberculosis drug-induced hepatitis. Hepatology 35(4), 883-889 (2002).
18. Cho HJ, Koh WJ, Ryu YJ et al.: Genetic polymorphisms of NAT2 and CYP2E1 associated with anti-Tuberculosis drug-induced hepatotoxicity in Korean patients with pulmonary Tuberculosis. Tuberculosis (Edinb.) 87(6), 551-556 (2007).
19. Vuilleumier N, Rossier MF, Chiappe A et al.: CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent Tuberculosis. Eur. J. Clin. Pharmacol. 62(6), 423-429 (2006).
20. Possuelo LG, Castelan JA, de Brito TC et al.: Association of slow N-acetyltransferase 2 profle and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur. J. Clin. Pharmacol. 64(7), 673-681 (2008).
21. Bozok Cetintas V, Erer OF, Kosova B et al.: Determining the relation between N-acetyltransferase-2 acetylator phenotype and anti-Tuberculosis drug induced hepatitis by molecular biologic tests. Tuberk. Toraks 56(1), 81-86 (2008).
22. Roy B, Chowdhury A, Kundu S et al.: Increased risk of anti-Tuberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J. Gastroenterol. Hepatol. 16(9), 1033-1037 (2001).
23. Huang YS, Su WJ, Huang YH et al.: Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J. Hepatol. 47(1), 128-134 (2007).
24. Leiro V, Fernandez-Villar A, Valverde D et al.: Infuence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of anti-Tuberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int. 28(6), 835-839 (2008).
25. Watanabe I, Tomita A, Shimizu M et al.: A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with Type 2 diabetes mellitus. Clin. Pharmacol. Ther. 73(5), 435-455 (2003).
26. Lucena MI, Andrade RJ, Martinez C et al.: Glutathione S-transferase M1 and T1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 48(2), 588-596 (2008).
27. Ghodke Y, Joshi K, Chopra A, Patwardhan B: HLA and disease. Eur. J. Epidemiol. 20(6), 475-488 (2005).
28. Lang C, Meier Y, Stieger B et al.: Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet. Genomics 17(1), 47-60 (2007).
29. Acuna G, Foernzler D, Leong D et al.: Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity. Pharmacogenomics J. 2(5), 327-334 (2002).
30. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP: Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 132(1), 272-281 (2007).
31. Choi JH, Ahn BM, Yi J et al.: MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet. Genomics 17(6), 403-415 (2007).
32. Aithal GP, Ramsay L, Daly AK et al.: Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39(5), 1430-1440 (2004).
33. Carr DF, Alfrevic A, Tugwood JD et al.: Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity. Pharmacogenet. Genomics 17(11), 961-972 (2007).
34. Hirata K, Takagi H, Yamamoto M et al.: Ticlopidine-induced hepatotoxicity is associated with specifc human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J. 8(1), 29-33 (2008).